ApidSOL™ Technology featured in a leading pharmaceutical journal


Topical tacrolimus skin penetration and ApidSOLTM technology probed for the first time by high spatial resolution X-ray microscopy…

Read More

ApidSOL™ Technology is the subject of a peer reviewed publication


New publication in the European Journal of Pharmaceutics and Biopharmaceutics is featuring ApidSOL™ technology and its delivery efficiency.…

Read More

Apidel has been invited to the 32nd Seminar in pharmaceutical sciences in Zermatt


Prof Robert Gurny, CSO and co-founder of Apidel has been invited at the 32nd Seminar in pharmaceutical sciences in Zermatt on August 27…

Read More

Apidel has received a granted patent from the USPTO


Apidel SA has the pleasure to announce that the patent application entitled "POLYLACTIDE COMPOSITIONS AND USES THEREOF" has been granted in…

Read More

Apidel at Advanced Functional Polymers for Medecine (AFMP) congress in Montpellier


Prof Robert Gurny, CSO and co-founder of Apidel is presenting ApidSOL™ micellar technology for improved local delivery at the Advanced…

Read More

ApidSOL™ technology featured at the 11th World Meeting on the Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.


Dr Naoual Dahmana is presenting the results of the project featuring ApidSOL™ technology at the 11th World Meeting on the Pharmaceutics,…

Read More

Polymer synthesis patent granted in Canada


Apidel SA has the pleasure to announced that the patent application related to the synthesis of its polymers "COMPOSITIONS COMPRISING…

Read More

Our ApidSOL™ Technology is the subject of a peer reviewed publication


A new publication mentioning our ApidSOL™ Technology has been published in the journal “Experimental Eye Research”. Kasper M. et al,…

Read More

Apidel reinforces its IP position in European territories


Multiple patents have been granted to Apidel SA for the protection of their pharmaceutical compounds and uses. Apidel has the pleasure to…

Read More

Apidel announces R&D collaboration with DNDi in the field of neglected disease


Apidel announces the signature of an agreement to collaborate with DNDi (Drugs for Neglected Diseases initiative) on the preclinical…

Read More